Home / Community / News / News

News

02/06/2018 - 9:52am

After a new review of the literature, the question of comorbidity of childhood DM1 and autism spectrum remains an open one.

01/07/2018 - 3:51pm

Discovery of the holy grail for DM therapy development-- drug registration endpoints -- lies in the dogged pursuit and sharing of natural history data.

01/07/2018 - 3:43pm

A new study examines the role of the GSK3β—cyclin D3—CUGBP1 pathway in the pathogenesis of DM1 and its potential as a therapeutic target.

01/07/2018 - 3:29pm

Development of a mini gene tool facilitates the identification of candidate therapeutics targeted at dissociating MBNL from expanded CUG repeats.

01/07/2018 - 3:20pm

NIH has reissued the CREATE Bio, Blueprint Neurotherapeutics and NeuroNEXT initiatives, along with other initiatives that focus on biomarker development and clinical trial readiness, to support therapy development efforts.

Partners

© Myotonic Dystrophy Foundation. All rights reserved.